<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02767999</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/14/7388</org_study_id>
    <nct_id>NCT02767999</nct_id>
  </id_info>
  <brief_title>Serotonin Selective Reuptake Inhibitor (SSRI) Effects on Cerebral Connectivity in Acute Ischemic Stroke</brief_title>
  <acronym>RECONISE</acronym>
  <official_title>Resting State MRI Connectivity in Acute Ischemic Stroke: Serotonin Selective Reuptake Inhibitor (SSRI) in Enhancing Motor Recovery: a Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fluoxetine action on cerebral connectivity changes in acute ischemic stroke patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this placebo-controlled study, using functional resting state MRI, the investigators aim
      to investigate cerebral connectivity changes induced by fluoxetine given once a day for 90
      days, in stroke patients with a moderate to severe motor deficit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intracerebral connectivity in the motor network between fluoxetine and placebo group.</measure>
    <time_frame>90 days</time_frame>
    <description>Intracerebral connectivity difference in the motor network, assessed by functional resting state MRI, between fluoxetine and placebo group after the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intracerebral connectivity in the motor network between good responders patients</measure>
    <time_frame>90 days</time_frame>
    <description>Intracerebral connectivity difference in the motor network, assessed by functional resting state MRI, in fluoxetine and placebo good responders patients, defined by :
8 points gain on the National Institute of Health Stroke Scale (NIHSS), assessed between D0 and D30 and between D0 and D90
or 2 points gain on the modified Rankin score (mRS) assessed between D0 and D30 and between D0 and D90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracerebral connectivity in the motor network between non-responders patients</measure>
    <time_frame>90 days</time_frame>
    <description>Intracerebral connectivity difference in the motor network, assessed by functional resting state MRI, in non-responders patients of fluoxetine and placebo group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Fluoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One group will take a 20 mg of fluoxetine capsule per day from D0 to D90 and have fMRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The other group will take a cellulose placebo per day from D0 to D90 and have fMRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>20 mg of fluoxetine capsule per day from D0 to D90</description>
    <arm_group_label>Fluoxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>cellulose placebo per day from D0 to D90</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fMRI</intervention_name>
    <description>functional resting state MRI</description>
    <arm_group_label>Fluoxetine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First-ever ischemic stroke

          -  Cortical or subcortical stroke

          -  National Institute of Health Stroke Scale NIHSS&gt;12 or motor NIHSS&gt;6 at inclusion

          -  MRI-proved ischemic stroke

        Exclusion Criteria:

          -  pregnant or breast-feeding women

          -  alcoholism

          -  ongoing Selective Serotonin Reuptake Inhibitor treatment or interruption &lt; 1 month

          -  allergic reaction after SSRI administration

          -  MRI contraindication

          -  NIHSS&gt;22

          -  Severe aphasia

          -  Coma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François CHOLLET, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marianne BARBIEUX-GUILLOT, MD</last_name>
    <phone>05.61.77.77.90</phone>
    <phone_ext>33</phone_ext>
    <email>barbieux-guillot.m@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Igor SIBON, Doctor</last_name>
      <email>igor.sibon@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne BARBIEUX-GUILLOT, MD</last_name>
      <phone>05.61.77.77.90</phone>
      <phone_ext>33</phone_ext>
      <email>barbieux-guillot.m@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2016</study_first_posted>
  <last_update_submitted>January 20, 2020</last_update_submitted>
  <last_update_submitted_qc>January 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute ischemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

